AR094025A1 - Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina - Google Patents

Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina

Info

Publication number
AR094025A1
AR094025A1 ARP130104755A ARP130104755A AR094025A1 AR 094025 A1 AR094025 A1 AR 094025A1 AR P130104755 A ARP130104755 A AR P130104755A AR P130104755 A ARP130104755 A AR P130104755A AR 094025 A1 AR094025 A1 AR 094025A1
Authority
AR
Argentina
Prior art keywords
body weight
insulin resistance
weight gain
prevention
bifidobacterium animalis
Prior art date
Application number
ARP130104755A
Other languages
English (en)
Inventor
Derrien Muriel
Shen Jian
Wang Jingjing
Zhao Liping
Saul Obin Martin
Original Assignee
Gervais Danone Sa
Univ Tufts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa, Univ Tufts filed Critical Gervais Danone Sa
Publication of AR094025A1 publication Critical patent/AR094025A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)

Abstract

La presente solicitud se refiere a la utilización de la cepa CNCM I-2494 de Bifidobacterium animalis subsp. lactis, para el uso en la disminución de la ganancia de peso corporal inducida por la dieta y el mejoramiento de la resistencia a la insulina inducida por la dieta, en un sujeto de experimentación.
ARP130104755A 2012-12-20 2013-12-16 Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina AR094025A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/087043 WO2014094279A1 (en) 2012-12-20 2012-12-20 Use of bifidobacterium animalis for treating or preventing body weight gain and insulin resistance

Publications (1)

Publication Number Publication Date
AR094025A1 true AR094025A1 (es) 2015-07-08

Family

ID=50977567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104755A AR094025A1 (es) 2012-12-20 2013-12-16 Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina

Country Status (10)

Country Link
US (1) US20150328266A1 (es)
EP (1) EP2935560A4 (es)
JP (1) JP6101818B2 (es)
CN (1) CN104884610A (es)
AR (1) AR094025A1 (es)
BR (1) BR112015014693A2 (es)
CA (1) CA2895963A1 (es)
MX (1) MX2015007971A (es)
RU (1) RU2015129066A (es)
WO (1) WO2014094279A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049352A1 (en) 2015-09-24 2017-03-30 Agriculture Victoria Services Pty Ltd Brachiaria endophytes and related methods
BR112018070518A2 (pt) * 2016-04-14 2019-01-29 Dupont Nutrition Biosci Aps bactéria do gênero bifidobacterium, usos de uma bactéria do gênero bifidobacterium e método para reduzir a ingestão de alimentos, energia e/ou gordura
RU2757213C2 (ru) * 2016-04-14 2021-10-12 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Бифидобактерии для увеличения безжировой массы тела
CN105853466B (zh) * 2016-05-06 2018-08-24 中国农业大学 双歧杆菌在制备用于预防和/或治疗因摄入酒精造成体重减轻的产品中的应用
BE1025428B1 (nl) * 2018-01-23 2019-02-14 Omega Pharma Innovation & Development Nv Voedingssupplement en gebruiken daarvan
CN109486715B (zh) * 2018-12-07 2022-07-15 江苏靶标生物医药研究所有限公司 一种富硒长双歧杆菌及其制备方法和应用
CN110923166A (zh) * 2019-12-11 2020-03-27 石家庄君乐宝乳业有限公司 动物双歧杆菌乳亚种jmcc0025、其分离纯化方法及应用
BR112022021309A2 (pt) * 2020-04-27 2022-12-06 Gervais Danone Sa Metabólitos de aminoácidos de cadeia ramificada e composição
CN113197311B (zh) * 2020-07-03 2023-06-23 内蒙古蒙牛乳业（集团）股份有限公司 一种乳酸菌组合物及其制备方法
CN113207961B (zh) * 2020-09-29 2023-06-23 内蒙古蒙牛乳业（集团）股份有限公司 乳双歧杆菌MN-Gup乳制品及其在改善2型糖尿病中应用
CN113197921B (zh) * 2020-09-29 2023-05-12 内蒙古蒙牛乳业（集团）股份有限公司 乳双歧杆菌MN-Gup及其菌剂在治疗2型糖尿病中的应用
CN113142303A (zh) * 2021-01-18 2021-07-23 重庆市天友乳业股份有限公司 一种具有预防肥胖功效的酸奶及其制备方法
CN113018319A (zh) * 2021-01-21 2021-06-25 中南大学 一种用于缓解因长期低剂量辐射暴露所致胰岛素抵抗的复合菌剂及其应用
CN112980725B (zh) * 2021-02-10 2022-11-11 中科微智（北京）生物科技有限公司 一种乳双歧杆菌及其在促进儿童青少年生长发育中的用途
JPWO2023068279A1 (es) * 2021-10-18 2023-04-27
CN114350547B (zh) * 2021-12-17 2023-05-16 四川省医学科学院·四川省人民医院 一种乳双歧杆菌菌株b-622及其在制备治疗糖尿病药物中的应用
CN114480229B (zh) * 2022-04-15 2022-08-09 微康益生菌(苏州)股份有限公司 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2811333B1 (fr) * 2000-07-04 2003-01-10 Gervais Danone Sa Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales et methode de selection desdits microorganismes
US20060228448A1 (en) * 2005-04-11 2006-10-12 The Iams Company Pet food compositions comprising two components
RU2492869C2 (ru) * 2008-05-26 2013-09-20 Компани Жервэ Данон СПОСОБ УМЕНЬШЕНИЯ УРЧАНИЯ В ЖИВОТЕ ПУТЕМ ВВЕДЕНИЯ БАКТЕРИЙ РОДА Bifidobacterium
CN104784219A (zh) * 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 治疗糖尿病及相关病症的双歧杆菌
CN102711778B (zh) * 2009-11-02 2015-06-24 热尔韦法国达能公司 利用动物双歧杆菌细菌或含有这种细菌的发酵乳制品减轻胃肠炎症的方法

Also Published As

Publication number Publication date
JP6101818B2 (ja) 2017-03-22
RU2015129066A (ru) 2017-01-23
MX2015007971A (es) 2016-03-09
EP2935560A4 (en) 2016-08-31
EP2935560A1 (en) 2015-10-28
WO2014094279A1 (en) 2014-06-26
BR112015014693A2 (pt) 2017-10-10
CN104884610A (zh) 2015-09-02
JP2016510311A (ja) 2016-04-07
US20150328266A1 (en) 2015-11-19
CA2895963A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
AR094025A1 (es) Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina
HK1226100B (zh) 雙歧桿菌乳酸亞種(bifidobacterium animalis subsp．lactis)cect 8145的新菌株及其用於治療和/或預防超重和肥胖症以及相關疾病的用途
CY1123404T1 (el) Αντι-girt αντισωματα
BR112016018283A2 (pt) Composição que compreende bifidobacterium animalis ssp. lactis
NZ629697A (en) Human anti-cd27 antibodies, methods and uses
BR112015002933A2 (pt) dispositivo implantável para uso no corpo humano e/ou animal para substituir uma válvula de um órgão.
NZ712959A (en) Probiotic strains for use in treatment or prevention of osteoporosis
MX2013006100A (es) Agente terapeutico que induce citotoxicidad.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
GB2511993A (en) Prebiotic formulations and methods of use
TN2012000414A1 (en) Forms of rifaximin and uses thereof
SG10201901922VA (en) Compositions and methods for treating metabolic disorders
BR112015010698A2 (pt) uso de uma linhagem de lactobacillus rhamnosus para a redução de ganho de peso e/ou de resistência a insulina
EP2796142A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DEATH CELLS OF LACTOBACILLUS ACIDOPHILUS LB STRAIN FOR THE TREATMENT OR PREVENTION OF ALLERGIC DISEASE
HK1209780A1 (en) Non-pathogenic f18 e. coli strain and use thereof f18
HK1198326A1 (zh) 用於預防或治療上呼吸道感染的鼠李糖乳桿菌和動物雙歧桿菌乳亞種
BR112016023752A2 (pt) utilização de lactobacillus rhamnosus para promover a recuperação da diversidade da microbiota intestinal após disbiose
WO2015121458A3 (fr) Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
GB2522188B (en) A lactobacillus reuteri GMNL-263 composition for controlling body weight and its use thereof
BR112015010639A2 (pt) lactobacillus rhamnosus para redução da acumulação de gordura corporal
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
WO2014096083A3 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthèse de mélanine
MX350212B (es) Nueva cepa de l.bulgaricus con capacidad de inhibir la adhesion de cepas de h. pylori a celulas epiteliales.
WO2012107601A8 (es) Uso de una cepa de lactobacillus bulgaricus para el tratamiento de la inmunosenescencia
ES2389364B1 (es) Procedimiento de preparacion, conservacion, y uso en peces, del probiotico shewanella putrefaciens pdp 11 para el control de enfermedades y la mejora en el crecimiento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure